- Home
- AMIX vs ADTX Comparison
AMIX vs ADTX Comparison
Compare AMIX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- ADTX
- Stock Information
- Founded
- AMIX 2014
- ADTX 2017
- Country
- AMIX United States
- ADTX United States
- Employees
- AMIX N/A
- ADTX N/A
- Industry
- AMIX
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- ADTX Health Care
- Exchange
- AMIX NYSE
- ADTX Nasdaq
- Market Cap
- AMIX 5.5M
- ADTX 5.3M
- IPO Year
- AMIX N/A
- ADTX 2020
- Fundamental
- Price
- AMIX $1.74
- ADTX $5.00
- Analyst Decision
- AMIX
- ADTX
- Analyst Count
- AMIX 0
- ADTX 0
- Target Price
- AMIX N/A
- ADTX N/A
- AVG Volume (30 Days)
- AMIX 41.8K
- ADTX 8.1M
- Earning Date
- AMIX 02-13-2025
- ADTX 05-19-2025
- Dividend Yield
- AMIX N/A
- ADTX N/A
- EPS Growth
- AMIX N/A
- ADTX N/A
- EPS
- AMIX N/A
- ADTX N/A
- Revenue
- AMIX N/A
- ADTX $133,985.00
- Revenue This Year
- AMIX N/A
- ADTX $95.61
- Revenue Next Year
- AMIX N/A
- ADTX $1,584.79
- P/E Ratio
- AMIX N/A
- ADTX N/A
- Revenue Growth
- AMIX N/A
- ADTX N/A
- 52 Week Low
- AMIX $1.52
- ADTX $4.11
- 52 Week High
- AMIX $75.80
- ADTX $35,000.00
- Technical
- Relative Strength Index (RSI)
- AMIX 33.31
- ADTX 33.28
- Support Level
- AMIX $1.69
- ADTX $4.17
- Resistance Level
- AMIX $2.11
- ADTX $7.69
- Average True Range (ATR)
- AMIX 0.17
- ADTX 1.92
- MACD
- AMIX -0.00
- ADTX 0.36
- Stochastic Oscillator
- AMIX 30.13
- ADTX 10.10
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.